Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

April 20, 2021 08:30 ET | Source: LEXEO Therapeutics

LEXEO Therapeutics Announces FDA Fast Track Designation Granted to LX1001 for the Treatment of APOE4 Associated Alzheimer’s Disease

LX1001 is the first investigational gene therapy being evaluated to address the underlying genetics of Alzheimer’s disease Initial Phase 1 clinical data expected in 2H 2021 NEW YORK, April 20,...
April 06, 2021 08:30 ET | Source: LEXEO Therapeutics

LEXEO Therapeutics Strengthens Management Team with Key Appointments to Accelerate Development of Clinical-Stage Pipeline

NEW YORK, April 06, 2021 (GLOBE NEWSWIRE) -- LEXEO Therapeutics, a clinical-stage gene therapy company, today announced the continued expansion of its management team with the appointments of two...
March 01, 2021 16:30 ET | Source: LEXEO Therapeutics

LEXEO Therapeutics Announces License Agreement and Consolidation of Comprehensive Pre-clinical Data Package to Support Cardiac Friedreich's Ataxia Gene Therapy Program (LX2006)

LEXEO completes license of all intellectual property rights and pre-clinical data associated with Adverum Biotechnologies’ investigational Friedreich’s ataxia program Pre-clinical research licensed...
January 07, 2021 07:30 ET | Source: LEXEO Therapeutics

LEXEO Therapeutics Launches with $85 Million Series A Financing to Develop Gene Therapies for Rare and Non-Rare Monogenic Diseases

Rare disease and gene therapy industry veterans Steven Altschuler, M.D., R. Nolan Townsend and Jay Barth, M.D., team up with gene therapy pioneer Ronald Crystal, M.D., to launch fully integrated gene...

keyboard_arrow_left Previous Page